Dexcom Inc

Strong Revenue Growth: Dexcom reported first-quarter 2025 revenue of $1.036 billion, representing a 12% increase year-over-year (YoY) and 14% organic growth. The U.S. revenue alone reached $751 million, marking a 15% increase from the prior year's quarter, driven by record new patient starts primarily from the type 2 non-insulin user segment.

Supply Chain Dynamics: Despite short-term supply issues that affected inventory, the company successfully normalized inventory levels by the end of Q1 2025. This was attributed to proactive measures taken by the team to minimize disruption and manage demand effectively.

Gross Margin Adjustments: The gross profit margin for Q1 2025 was 57.5%, down from 61.8% in Q1 2024. Guidance was updated to reflect adjusted full-year gross profit margin expectations of approximately 62%, influenced by supply chain costs and inflationary pressures, including a 50 basis point impact from tariffs.